Biogen Inc. BIIB
NASDAQ · United States · Health Technology
$225.88-1.19 (-0.52%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Earlier this month, Eisai and Biogen secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, while Biogen also published Phase 3 VALIANT adolescent subgroup data showing EMPAVELI improved proteinuria and stabilized kidney function in rare complement-mediated kidney disorders. Together, these updates highlight Biogen’s push to make complex therapies more accessible in real-world settings, potentially broadening treatment reach in both...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.